Richard Levy Bought 65% More Shares In Protara Therapeutics

Even if it's not a huge purchase, we think it was good to see that Richard Levy, the Independent Director of Protara Therapeutics, Inc. (NASDAQ:TARA) recently shelled out US$64k to buy stock, at US$3.19 per share. Even though that isn't a massive buy, it did increase their holding by 65%, which is arguably a good sign.

Our free stock report includes 3 warning signs investors should be aware of before investing in Protara Therapeutics. Read for free now.

The Last 12 Months Of Insider Transactions At Protara Therapeutics

Notably, that recent purchase by Richard Levy is the biggest insider purchase of Protara Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$3.19. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the Protara Therapeutics insider decided to buy shares at close to current prices. Richard Levy was the only individual insider to buy during the last year.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Check out our latest analysis for Protara Therapeutics

Protara Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Does Protara Therapeutics Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Based on our data, Protara Therapeutics insiders have about 2.5% of the stock, worth approximately US$3.1m. We consider this fairly low insider ownership.

What Might The Insider Transactions At Protara Therapeutics Tell Us?

It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Protara Therapeutics stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To help with this, we've discovered 3 warning signs (2 shouldn't be ignored!) that you ought to be aware of before buying any shares in Protara Therapeutics.

Of course Protara Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.